(Q24203875)

ORCID Public Data File 2021

author name string

Kay Wang

1

0 references

Matthew Shun-Shin

2

0 references

Peter Gill

3

0 references

Anthony Harnden

Cochrane Database of Systematic Reviews

5

0 references

publication date

18 January 2012

0 references

published in

0 references

cites work

Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Safety and pharmacology of oseltamivir in clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

The effect of zanamivir treatment on influenza complications: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Safety and pharmacokinetics of oseltamivir at standard and high dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Use of Oseltamivir to control influenza complications after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Experience with oseltamivir for infants younger than 1 year old in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Investigation of the Reconsultation Rate and Pharmacoeconomic Evaluation of Period of Influenza Treatment by Oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Relative impact of influenza and respiratory syncytial virus in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

The global state of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Time to publication for results of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Influenza and the rates of hospitalization for respiratory disease among infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children - a review of clinical study reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Estimating household and community transmission parameters for influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Neuraminidase inhibitors for preventing and treating influenza in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Clinical prediction rules combining signs, symptoms and epidemiological context to distinguish influenza from influenza-like illnesses in primary care: a cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Neuraminidase inhibitors for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Rapid diagnostic testing for seasonal influenza: an evidence-based review and comparison with unaided clinical diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

The underrecognized burden of influenza in young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Evaluation of diagnostic tests for influenza in a pediatric practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Guidelines on neuraminidase inhibitors in children are not supported by evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Systematic review of influenza resistance to the neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Position statement: global neuraminidase inhibitor susceptibility network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Neuraminidase inhibitors for preventing and treating influenza in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

Duration of isolation of children with influenza A treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

7 January 2021

Respiratory distress associated with zanamivir

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

7 January 2021

Oseltamivir phosphate in infants under 1 year of age with influenza infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

7 January 2021

An evidence based approach to reducing antibiotic use in children with acute otitis media: controlled before and after study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

7 January 2021

Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

1 reference

7 January 2021

Effect of Influenza Treatment with Oseltamivir on Health Outcome and Costs in Otherwise Healthy Children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

7 January 2021

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002744.PUB3

7 January 2021